Reference priceJPY ¥770.00Original source price: INR 440.00. Converted estimates are available by currency selection.
| Brand | Skyriz |
|---|---|
| Manufacturer | AbbVie Inc |
| Prescription required | Yes |
Skyriz 55mg/0.37ml Syringes,1per x 0.37ml (risankizumab-rzaa)
risankizumab-rzaa
Description
Skyriz 55mg/0.37ml Syringes,1per x 0.37ml (risankizumab-rzaa) is a medicine catalog record in the MediPriceHub database. Active ingredient: risankizumab-rzaa. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: AbbVie Inc. Therapeutic category: Medicine Library > Dermatology Medicines > Drugs for psoriasis. Pack information: 55 / 0.37, 1. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. active psoriatic arthritis in adults and pediatric patients 6 years of age and older. moderately to severely active Crohn's disease in adults. moderately to severely active ulcerative colitis in adults. 1.1 Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older. 1.3 Crohn’s Disease SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults. 1.4 Ulcerative Colitis SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.How to Use
Use risankizumab-rzaa under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: risankizumab-rzaa. Pack size: 55 / 0.37, 1. Pack unit: tube. Manufacturer: AbbVie Inc. Origin country: United States. Source category: Medicine Library > Dermatology Medicines > Drugs for psoriasis. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Possible adverse effects vary by active ingredient, dose, route, treatment duration, and patient condition. Common issues may include gastrointestinal symptoms, headache, dizziness, fatigue, rash, allergic reactions, or abnormal laboratory tests. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。